Wealthedge Investment Advisors’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$228K Sell
20,453
-4,500
-18% -$54.7K 0.08% 134
2026
Q1
$348K Sell
24,953
-51,443
-67% -$721K 0.13% 109
2025
Q4
$1.1M Sell
76,396
-440,861
-85% -$6.63M 0.41% 69
2025
Q3
$8.23M Buy
517,257
+394,128
+320% +$6.49M 3.12% 4
2025
Q2
$2.18M Buy
+123,129
New +$2.4M 0.91% 31

Other funds holding BTAL

Wealthedge Investment Advisors's BTAL Position: Q2 2026 in Review

Wealthedge Investment Advisors reduced its AGF US Market Neutral Anti-Beta Fund (BTAL) stake by 18% in Q2 2026, selling an estimated $54.7K and leaving 20,453 shares worth $228K. The position accounts for 0.08% of the portfolio, ranked #134.

Wealthedge Investment Advisors first reported a position in BTAL in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.23M in Q3 2025. 93 funds tracked by Wall St. Rank hold BTAL as of Q2 2026.

  • Wealthedge Investment Advisors held 20,453 shares of AGF US Market Neutral Anti-Beta Fund worth $228K as of Q2 2026.
  • Wealthedge Investment Advisors sold 4,500 AGF US Market Neutral Anti-Beta Fund shares in Q2 2026, an estimated $54.7K.
  • AGF US Market Neutral Anti-Beta Fund made up 0.08% of Wealthedge Investment Advisors's portfolio in Q2 2026, its #134 holding.
  • Wealthedge Investment Advisors first reported a position in AGF US Market Neutral Anti-Beta Fund in Q2 2025 and has held it in 5 quarters since.
  • Wealthedge Investment Advisors's AGF US Market Neutral Anti-Beta Fund position peaked at $8.23M in Q3 2025.
  • 93 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q2 2026.

Based on Wealthedge Investment Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.